Cholesterol Lowering and Residual Risk in Diabetes, Type 1

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.

Also called NCT05641753

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 125 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05641753
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05641753. Allocation not applicable; no masking; primary purpose other. Start 2022-12-06 (actual); primary completion 2027-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Acronym
CHORD1
Condition
Type 1 Diabetes
Intervention (Drug)
Evolocumab Cartridge
Intervention (Drug)
Atorvastatin Calcium Tablets
Intervention (Drug)
Ezetimibe Tablets
Intervention (Drug)
18F-FDG
Intervention (Device)
Angiocatheter 20IV
Intervention (Device)
J-Wire
Intervention (Device)
GlycoCheck Glycocalyx Measurement Software
Lead sponsor
NYU Langone Health (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05641753
Content hash
9a11ede16340a941c230403659a54caa0e44afa56a4143939245f7a402ebd5e8